Compare Hershey Co (HSY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Novartis AG — how do they compare? Hershey Co trades at $180.9 (market cap $36.56B), while Novartis AG trades at $152.86 (market cap $295.37B). The key difference: Novartis AG is far larger — about 8.1× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| HSY | NVS | |
|---|---|---|
Market Cap | $36.56B | $295.37B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $168.62 |
52-Week Low | $162.31 | $119.31 |
Enterprise Value | $41.70B | $336.69B |
Dividend Yield | 3.19% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $182.75, up 0.22% with a bullish technical signal and strong fundamental momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $1.90 exceeding expectations by 33%, while revenue growth trends upward to $11.69 billion in 2025. Analyst consensus targets $196.78 with 69% hold ratings, reflecting cautious optimism amid margin recovery from favorable cocoa contracts and dividend growth.
The outlook remains positive with earnings rebound and pricing power, though risks include volume declines and competitive pressures. Current valuation at 24.86 P/E appears reasonable given 32.81% ROE and improving cash flow trends. Institutional sentiment is mixed with recent insider sales offset by upward guidance revisions.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
